Drug manufacturer Eli Lilly's weight loss pill has completed late-stage trials for people with type 2 diabetes. The pill could offer an alternative to injectables. US general details China ...

The global weight-loss drug ... Eli Lilly (LLY) and Novo Nordisk (NVO), dominate this market. Both companies have created GLP-1 receptor agonists that have transformed obesity treatment: Eli Lilly ...

Eli Lilly’s new GLP-1 weight loss drug, in pill form, would be more affordable than Ozempic Orforglipron, which could become the first GLP-1 pill — a much more convenient option — is a step ...

If approved, the pill is expected to be far easier to administer than current injectables - and far easier to manufacture Eli Lilly ... Novo's injectable Ozempic in diabetes, and shows weight loss ...

Pharmaceutical company Eli Lilly ... it's a once-a-day weight management pill. However, the pharmaceutical firm ran into some trouble two years into developing and testing the drug, finding ...

Eli Lilly's oral GLP-1 medicine aced a phase 3 study. It should become a new growth driver for the company. There are other reasons to invest in the pharmaceutical leader. Zepbound's prospects ...

Regeneron also said it will license an experimental obesity drug from China's Hansoh Pharmaceuticals ... billion. Weight-loss drugs from current market leaders Novo Nordisk and Eli Lily (LLY.N ...

Eli Lilly (NYSE: LLY) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in ...